An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

RecruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

December 28, 2023

Primary Completion Date

July 30, 2026

Study Completion Date

October 31, 2026

Conditions
Pulmonary HypertensionInterstitial Lung Disease
Interventions
COMBINATION_PRODUCT

LIQ861

trepostinil inhalation powder

Trial Locations (23)

10016

RECRUITING

NYU Langone Medical Center, New York

14627

RECRUITING

University of Rochester, Rochester

27514

RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

29425

RECRUITING

Medical University of South Carolina, Charleston

32803

RECRUITING

Advent Health, Orlando

33606

RECRUITING

Tampa General Hospital Center of Research Excellence, Tampa

40241

RECRUITING

Norton Pulmonary Specialists, Louisville

45219

RECRUITING

University of Cincinnati Health, Cincinnati

46260

RECRUITING

Vincent Medical Group, Indianapolis

48109

RECRUITING

University of Michigan, Ann Arbor

55455

RECRUITING

University of Minnesota, Minneapolis

77030

RECRUITING

Houston Methodist, Houston

80206

RECRUITING

National Jewish Health, Denver

84112

RECRUITING

University of Utah, Salt Lake City

85012

RECRUITING

Arizona Pulmonary Specialists, Phoenix

90095

RECRUITING

UCLA Westwood, Los Angeles

92093

RECRUITING

University of California San Diego, La Jolla

93720

RECRUITING

The Medical Research Group, Inc., Fresno

94143

RECRUITING

UCSF, San Francisco

95817

RECRUITING

UC Davis, Sacramento

97701

RECRUITING

Summit Health, Bend

06102

RECRUITING

Hartford Hospital, Hartford

02111

RECRUITING

Tufts Medical Center, Boston

Sponsors
All Listed Sponsors
lead

Liquidia Technologies, Inc.

INDUSTRY

NCT06129240 - An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH | Biotech Hunter | Biotech Hunter